Q1 2025 marked another strong quarter for life sciences VC financing, but the industry faces unique headwinds amid ongoing shake-ups in regulatory leadership and US trade relationships. Key takeaways for Q1 2025 include: • Industry dealmaking maintained momentum in Q1 2025 after closing out its first year of cumulative value growth since 2021. Quarterly deal value grew 10.6% QoQ, while deal count dropped 15.0%.
Please see full publication below for more information.
